At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Hypofractionated Radiation Therapy After Mastectomy in Patients With Stage IIa-IIIa Breast Cancer
This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
In order to participate you must meet the following criteria:
- Have histologically confirmed invasive carcinoma of the breast of any of the following histologies: ductal, lobular, mammary, medullary, or tubular.
- Have had no prior therapeutic radiation therapy to the chest, neck or axilla. Prior radioactive oral iodine is permitted.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
You will be excluded from the study if any of the following criteria apply to you:
- Have clinical or radiological evidence of metastatic disease.
This is a partial list of inclusion and exclusion criteria.